ALLSCHWIL/BASEL, Switzerland, April 30, 2004 (PRIMEZONE) -- At today's Annual General Meeting of Actelion Ltd (SWX:ATLN), shareholders approved the following resolutions:
-- Increase of conditional capital by CHF 2.25 million (0.9 million shares), reserved for the issuance of employee stock options
-- Increase of conditional capital by CHF 5 million (2 million shares), reserved for issuance of employee stock options in connection with a special one-time incentive plan linked to specific achievements by the Company
-- Extension of the period for the Authorized Capital of CHF 10,000,000 until 30 April 2006
The shareholders also approved the annual report, including the financial statements, for the year 2003. They also elected Armin Kessler and Jean Malo to serve on the Actelion Board of Directors. The shareholders also confirmed Werner Henrich as a member of the board for another three years.
Following the departure of former board members Joel Besse and Rudolf Maag, the board of directors continues to be composed of 7 members: Robert E. Cawthorn (Chairman), Andre J. Mueller (Vice-Chairman), Jean-Paul Clozel, Werner Henrich, Fred J. Meyer, Armin Kessler and Jean Malo.
The Annual General Meeting of Actelion took place in Basel. It was attended by 147 shareholders, representing 8,316,425 shares or 37.90 percent of the total outstanding shares.
Actelion Ltd
Actelion Ltd is a biopharmaceutical company with its corporate headquarter in Allschwil/Basel, Switzerland. Actelion's first drug, Tracleer(R), an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer(R) through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union as well as Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium -- the single layer of cells separating every blood vessel from the blood stream. Actelion focuses on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SWX Swiss Exchange (ticker symbol: ATLN).
For further information please contact:
Actelion Ltd, Gewerbestrasse 16, CH-4123 Allschwil Investor Contact Roland Haefeli +41 61 487 34 58 +1 650 624 6936 Media Contact Peter Engel +41 61 487 36 28 http:// www.actelion.com